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Strengths and limitations of this study
 ► The Congenital Diaphragmatic hernia Nitric Oxide 
versus Sildenafil (CoDiNOS) trial is the first ran-
domised controlled multicentre trial to evaluate the 
effect of intravenous sildenafil and compare with 
inhaled nitric oxide (iNO) on pulmonary hypertension 
in newborns with congenital diaphragmatic hernia 
(CDH).
 ► Treatment allocation is not blinded in the trial. This 
is not feasible because of variability in iNO equip-
ment and gas mixtures use. Instead, the research-
ers who analyse the echocardiography to evaluate 
pulmonary hypertension (PH) will be blinded to the 
treatment.
 ► The primary outcome, PH, will be measured using 
echocardiography instead of just clinical parameters 
often used in newborns.
 ► There is no non- intervention group, as it is common 
practice in the centres of the CDH EURO Consortium 
to give iNO; hence, it is considered unethical to with-
hold treatment for one group.
 ► Long- term follow- up of 12 months will give more 
insight in the course of PH in infants.
AbStrACt
Introduction Congenital diaphragmatic hernia (CDH) 
is a developmental defect of the diaphragm that 
impairs normal lung development, causing pulmonary 
hypertension (PH). PH in CDH newborns is the main 
determinant for morbidity and mortality. Different therapies 
are still mainly based on ‘trial and error’. Inhaled nitric 
oxide (iNO) is often the drug of first choice. However, iNO 
does not seem to improve mortality. Intravenous sildenafil 
has reduced mortality in newborns with PH without CDH, 
but prospective data in CDH patients are lacking.
Methods and analysis In an open label, multicentre, 
international randomised controlled trial in Europe, Canada 
and Australia, 330 newborns with CDH and PH are recruited 
over a 4- year period (2018–2022). Patients are randomised 
for intravenous sildenafil or iNO. Sildenafil is given in a 
loading dose of 0.4 mg/kg in 3 hours; followed by continuous 
infusion of 1.6 mg/kg/day, iNO is dosed at 20 ppm. Primary 
outcome is absence of PH on day 14 without pulmonary 
vasodilator therapy and/or absence of death within the first 
28 days of life. Secondary outcome measures include clinical 
and echocardiographic markers of PH in the first year of life. 
We hypothesise that sildenafil gives a 25% reduction in the 
primary outcome from 68% to 48% on day 14, for which a 
sample size of 330 patients is needed. An intention- to- treat 
analysis will be performed. A p- value (two- sided) <0.05 is 
considered significant in all analyses.
Ethics and dissemination Ethics approval has been 
granted by the ethics committee in Rotterdam (MEC-2017-
324) and the central Committee on Research Involving 
Human Subjects (NL60229.078.17) in the Netherlands. 
The principles of the Declaration of Helsinki, the Medical 
Research Involving Human Subjects Act and the national 
rules and regulations on personal data protection will be 
used. Parental informed consent will be obtained.
trial registration number NTR6982; Pre- results.
IntroduCtIon
Congenital diaphragmatic hernia (CDH) is a 
severe developmental defect of the diaphragm 
with an incidence of approximately 1 in 3000 
live births and a mortality of 27%.1 Because 
of this defect, the abdominal organs herniate 
into the chest causing pulmonary hypo-
plasia and abnormal pulmonary vasculature 
growth, resulting in pulmonary hypertension 
(PH).2 In adults and children, PH is defined 
as mean pulmonary artery pressure (mPAP) 
exceeding 25 mm Hg with a pulmonary capil-
lary wedge pressure of minimal 15 mm Hg.3
The normal pulmonary vascular transition 
of the neonate takes around 2 months to 
achieve these low values of mPAP. During fetal 
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life, there is high resistance in the pulmonary circulation 
which results in most of the blood flow to bypass the lungs 
through the ductus arteriosus and oval foramen. Immedi-
ately after birth, the pulmonary vascular resistance drops 
and the blood flow to the lungs significantly increases.4 
In contrast, the pulmonary vascular resistance often 
does not drop adequately in children with CDH due to 
a decreased vascular bed associated with lung hypoplasia, 
and an altered development of the pulmonary vascula-
ture with excessive muscularisation of the arterioles, 
with increased thickness of the arterial media and adven-
titia. Although the presence of lung hypoplasia can be 
predicted with prenatal parameters, reliable predictors 
for PH in CDH patients are lacking.5 The incidence of 
PH in CDH patients is 68%–79% and causes considerable 
morbidity and mortality.1 2 6 Therapy in newborns with 
PH, such as inhaled nitric oxide (iNO) and sildenafil, has 
improved outcomes in general. However, trials in infants 
with CDH are sparse.
iNO diffuses rapidly across the alveolar- capillary 
membrane into the smooth muscle of pulmonary vessels 
to activate soluble guanylate cyclase. This enzyme mediates 
many of the biological effects of iNO, and is responsible 
for the conversion of guanosine triphosphate (GTP) to 
cyclic guanosine monophosphate (cGMP). The increase 
of intracellular cGMP relaxes smooth muscles via several 
mechanisms. iNO also causes bronchodilation and has 
anti- inflammatory and anti- proliferative effects.7 In term 
and near term infants with persistent pulmonary hyperten-
sion of the newborn (PPHN), iNO decreases the median 
duration of mechanical ventilation and reduces the need 
for extracorporeal membrane oxygenation (ECMO). 
However, in the two available randomised controlled trials 
(RCT) with a small number of patients with CDH, mortality 
did not improve and more ECMO treatment was needed 
despite short- term improvement of oxygenation in some 
treated patients.8 9 In the centres of the CDH EURO Consor-
tium, iNO is standard of care in infants with CDH and PH 
although the positive pharmacodynamic effects in these 
infants are less convincing than in infants with PPHN.6 10 
The pathophysiological mechanism of this difference is not 
understood. In resource poor settings iNO is often unavail-
able. In the search to find another treatment option, trials 
to evaluate the effect of sildenafil in newborns with PPHN 
have been conducted.11
Sildenafil is a selective phosphodiesterase type 5 (PDE5) 
inhibitor. PDE5 is an enzyme that specifically degrades 
cGMP. Sildenafil inhibits PDE5, increasing cGMP and 
nitric oxide- mediated vasodilatation of the smooth 
muscles in arteries. Only five RCTs have been performed 
in newborns, all non- CDH patients with PPHN. Four of 
these studies showed a decrease in oxygenation index 
(OI) and mortality in a setting where iNO was not avail-
able, while one trial showed no additional benefit of 
sildenafil when added to iNO.11 Although sildenafil is 
increasingly used in CDH patients, only retrospective 
data are available.12 A decrease in pulmonary vascular 
resistance index and an increase in cardiac output were 
found in a small group of oral sildenafil- treated infants 
with CDH refractory to iNO.13 Intravenous sildenafil 
improved OI and reversed the right- to- left shunt ratio 
over the PDA, but it also increased the need for inotropic 
support.14 15 However, its effect on outcome is unknown.
We hypothesise that intravenous sildenafil is superior 
to iNO. iNO is the therapy of first choice in most centres 
despite the lack of evidence, and sildenafil is the most 
promising drug for the treatment of PH in CDH patients 
and is increasingly being used.6 12 16 However, no studies 
have been performed comparing iNO with intravenous 
sildenafil in newborns with CDH and PH or PH alone. 
Based on the current knowledge, there is equipoise for 
both treatment modalities.
MEthodS And AnAlySIS
design
The Congenital Diaphragmatic hernia Nitric Oxide versus 
Sildenafil (CoDiNOS) trial is a prospective, multicentre, 
international RCT conducted in high volume paediatric 
surgical centres in Europe, Canada and Australia. The 
members of the CDH Euro Consortium participating in 
the trial are listed in the online supplementary appendix.
objectives
The primary objective of the study is to determine whether 
the incidence of PH is lower in CDH patients treated with 
intravenous sildenafil than in patients treated with iNO, 
with the primary outcome defined as the absence of PH 
on echocardiography on day 14 without pulmonary vaso-
dilator therapy and without treatment failure and/or death 
within the first 28 days after birth. PH is defined as systolic 
pulmonary arterial pressure >2/3 systolic systemic pressure 
and/or right ventricular (RV) dilatation/septal displace-
ment and RV dysfunction +/−left ventricular dysfunction.
The secondary outcomes are:
1. Change in OI after 12 and 24 hours of therapy.
2. Overall mortality.
3. The incidence of treatment failure which is defined 
as:
 – inability to maintain preductal saturations above 
85% (±7 kPa or 52 mm Hg) or postductal satura-
tions above 70% (±5.3 kPa or 40 mm Hg).
 – and/or increase in CO2 >70 mm Hg (9.3 kPa) de-
spite optimisation of ventilator management.
 – and/or inadequate oxygen delivery with metabolic 
acidosis defined as lactate ≥5 mmol/L and pH <7.15 
and/or hypotension resistant to fluid therapy and 
adequate inotropic support resulting in a urine out-
put <0.5 mL/kg/hour.
 – and/or lactate ≥5 mmol/L and pH <7.15.
 – and/or OI consistently ≥40.
4. Time on intervention drug, defined as intervention 
drug free days after initiation of the intervention, cal-
culated on day 14.
5. Need for ECMO.
6. Ventilator free days on day 28.
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7. The use of drugs for PH treatment during the hospi-
tal admission.
8. The use of pulmonary and/or cardiac medication at 
discharge and its total duration of administration.
9. Short- term and long- term PH on echocardiography 
at 24 hours, 28 days/discharge and 6 and 12 months.
10. The incidence of chronic lung disease.
11. The development of neurological abnormalities eval-
uated with ultrasound of the brain before the start of 
the trial, after surgery and before discharge.
12. The external validation of the sildenafil pharmaco-
kinetic - pharmacodynamic (PKPD) model for the 
pharmacokinetics and the pharmacodynamic effects 
of sildenafil.
Safety outcomes include adverse events due to the study 
drugs and the vasoactive- inotropic support (VIS) score.
Patients
Infants diagnosed with CDH who have PH in the first 
week after birth are eligible for the trial if born at or 
after a gestational age of 34 weeks. The diagnosis of PH 
is defined as at least two of the following four criteria: 
(1) systolic pulmonary arterial pressure >2/3 systolic 
systemic pressure estimated by echocardiography, (2) RV 
dilatation/septal displacement, RV dysfunction +/−left 
ventricular dysfunction, (3) pre- post ductal SpO2 differ-
ence >10%, (4) OI >20. Exclusion criteria are a severe 
chromosomal anomaly which may imply a decision to 
stop or not to start life- saving medical treatment, severe 
cardiac anomaly expected to need corrective surgery in 
the first 60 days of life, renal anomalies associated with 
oligohydramnios, severe orthopaedic and skeletal defor-
mities, which are likely to influence thoracic, and/or lung 
development and severe anomalies of the central nervous 
system. Patients who are born in another centre and trans-
ported with iNO are also excluded from the trial. Patients 
who received fetal interventions (trachea balloon place-
ment) are not excluded.
Following antenatal diagnosis, the parents are coun-
selled and informed about the study by the clinician or 
research coordinator. Also, they receive a patient infor-
mation letter and an informed consent form . If the 
patient is not born in a participating centre or the diag-
nosis of CDH was not known, parents are counselled after 
the diagnosis of CDH and are informed about the study. 
Also, they receive written information and an informed 
consent form. This informed consent form contains 
consent for the trial and for collection of data and mate-
rial for future research.
For the development of the protocol the SPIRIT 
reporting guidelines have been used.17 This publication 
is based on protocol V.4, 13 June 2018.
Patient and public involvement
Patients and the public were not involved in the develop-
ment of the trial protocol. However, CDH UK Sparks, as 
a parent organisation, has assessed and commented on 
the protocol and has provided start- up funding as also 
mentioned in the funding statement. This organisation is 
and will be regularly informed on progress and results of 
the trial.
Study procedures
 Baseline assessment
Antenatal ultrasound data about the characteristics of 
the CDH are collected. These data include the observed/
expected lung- head ratio, position of the liver and 
stomach and the amniotic fluid index. An MRI or an 
ultrasound is performed depending on local experience 
and possibilities. If an MRI is performed, the observed/
expected fetal lung volume will be calculated. Also data 
on prenatal interventions are collected. In all mothers, a 
planned vaginal or caesarean delivery is pursued.
 Randomisation, intervention and blinding
Participants will be randomised using ALEA, which is an 
online, central randomisation service (https://www. alea-
clinical. eu). Allocation concealment will be ensured, as 
the service will not release the randomisation code until 
the patient has been recruited into the trial, which takes 
place after all baseline characteristics have been added. 
ALEA randomises the patient with a computer- generated 
randomisation list, made by the independent statistician 
of the Data Safety and Monitoring Board. Blocked rando-
misation, with variable block sizes and stratification by 
centre, is used to achieve equal distribution of the two 
interventions among the participants.
Postnatally, infants are treated according to a stan-
dardised protocol for patients with CDH, which is imple-
mented in all participating centres. This protocol was 
developed with the available evidence and consensus 
between the participating centres and was updated in 
June 2016.10 16 If the patient is diagnosed with PH in the 
first week of life, the patient will be allocated to one of 
the two study drugs (figure 1). iNO is provided by a tank 
connected to a ventilator. Different devices are used in 
different centres. Some centres use integrated systems, 
making it impossible to disconnect the iNO tank and 
replace it with another gas to facilitate a blinded inter-
vention. Therefore, the study is open label. iNO is given 
with a starting dose of 20 ppm, which is the maximum 
dose.18 19 Sildenafil is given intravenously, using a loading 
dose of 0.4 mg/kg in 3 hours, followed by continuous 
infusion of 1.6 mg/kg/day.20 21 To wean the study drugs 
a standard protocol is followed (figure 2). The allo-
cated drugs will be restarted as per protocol if criteria 
for its use are met again before the age of 14 days. To 
further standardise care, an inotropic support flow chart 
is included in the study protocol (figure 3). After day 
14 treatment of PH will be at the discretion of the local 
medical team and the study drug can be changed to, for 
instance, sildenafil orally. The use of bosentan, milri-
none and prostin next to the study treatment is allowed. 
The use of bosentan as add on therapy is allowed and is 
considered as PH treatment on day 14. The intervention 
will be prematurely stopped when the patient meets one 
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Figure 1 Trial flow chart. Flow chart showing the steps of the trial, from birth until 12 months. CoDiNOS, Congenital 
Diaphragmatic hernia Nitric Oxide versus Sildenafil;CDH, congenital diaphragmatic hernia; SAE, serious adverse event; SUSAR, 
suspected unexpected serious adverse reaction.
or more of the defined failure criteria, described in point 
three of the secondary outcomes. Further treatment will 
then be at the discretion of the medical team and will 
be according to the standardised protocol.16 iNO and 
sildenafil can both be given outside the study protocol. 
An ECMO procedure may then be started in centres 
where ECMO is available. Data of all patients are used in 
the intention- to- treat analysis.
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Figure 2 Protocol to wean study drug. Flow chart showing the protocol to wean off inhaled nitric oxide or intravenous 
sildenafil. INO, inhaled nitric oxide.
Figure 3 Treatment flow chart of systemic hypotension. Flow chart that is added to the treatment protocol, showing the 
treatment plan for systemic hypotension. LV, left ventricular; SVR, systemic vascular resistance; VA ECMO, veno- arterial 
extracorporeal membrane oxygenation; ?, if available.
 Follow up
After day 14, additional clinical data, such as time on venti-
lator support (days) and the use of drugs for the treatment 
of PH, are collected to answer the secondary outcome ques-
tions. Also, echocardiographic measurements are taken at 
6 and 12 months to evaluate the presence of chronic PH 
(table 1).
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 Data collection
Echocardiography parameters are measured by local 
physicians, centrally collected and reviewed by two 
blinded independent physicians to reduce inter- observer 
variation. Demographic and neonatal characteristics 
as well as data on the clinical course of all patients are 
entered in a password protected web- based database in 
Rotterdam (OpenClinica). On request the collected data 
will be available. All centres will keep a logbook of the 
number of non- participants, including the reasons for 
not participating. Study documents are securely stored at 
each study site for 15 years.
 Laboratory testing
Blood, urine and tracheal samples are collected in most 
centres during the trial. Blood samples are collected 
before the start of the study and at different time points 
until day 14. Some samples will be used to externally vali-
date a NONlinear Mixed Effects Modeling (NONMEM) 
prediction model for sildenafil. The other samples will be 
used in future research on biomarkers to predict severity 
and outcome of PH in CDH patients. The samples are 
centrifuged for 6 min at 3000 rpm.22 Thereafter, the 
plasma is removed and stored at –20°C or colder. The 
total amount of blood taken is maximal 2.5% of the 
circulating volume. Blood sampling will only be done if a 
central or peripheral line is still present and/or in combi-
nation with routine laboratory measurements. This way 
blood sampling is a minimal burden for the patient.
Tracheal aspirate for proteomic analysis is also 
collected at different time points during routine tracheal 
suctioning in ventilated patients. Protein profiling with 
proteomics is used to identify specific groups of proteins 
that are involved in the pathogenesis of PH. The tracheal 
aspirates is centrifuged for 6 min at 3000 rpm and stored 
at –80°C.23
Also, 8 hour urine is collected at different time points. 
Two samples of 5 mL are taken and stored at –20°C or 
colder.
 Withdrawal of participants
Parents may decide to withdraw from the study at any time 
without any consequences. The investigator can decide 
to withdraw a patient from the study for urgent medical 
reasons. In some cases, there may be exclusion criteria, 
which were not known before randomisation. If this is the 
case, the patient will be withdrawn from the study after 
contacting the study coordinator. With consent of the 
parents data will still be collected, stored and analysed to 
perform an intention- to- treat analysis. These children will 
be treated according to standard practice.10 16
Sample size calculation
The sample size calculation is based on a power analysis 
for the primary outcome, using previously published 
data on PH. Lusk et al showed that PH, defined as >2/3 
systemic blood pressure measured on echocardiography, 
in CDH patients on day 14 has a positive predictive value 
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of 0.8 for death, death or ventilation, and death or venti-
lator support. PH on day 14 is observed in 64% of CDH 
patients.24
Even though the definition of the primary outcome is 
not the same, we assume a similar outcome percentage 
of 64% for failing the primary outcome in our trial, the 
absence of PH on day 14 without pulmonary vasodilator 
therapy and/or absence of death within the first 28 days 
of life, in the iNO group. Our aim is to promote prac-
tice change; therefore, we aim for a clinically significant 
difference. For a 25% relative reduction to 48%, a sample 
size of 300 patients (150 patients per group) is needed to 
obtain a power of 80%. This will match a number needed 
to treat of 6.25. Taking missing data and the effects of 
correction for covariates into account, we adjust this 
sample size to 330 patients. In the collaborating centres 
550 patients will be born in 3 years. Based on our earlier 
trial (CMV Versus HFO in Congenital Diaphragmatic 
Hernia; VICI trial) we expect to have an inclusion rate of 
60%. Therefore, the inclusion of 330 patients should be 
reached in 3 years.
data analysis
The patients will be analysed according to the group they 
are randomised to (intention- to- treat analysis). A p- value 
(two- sided) <0.05 is considered significant in all analyses. 
The primary endpoint will be analysed using multiple 
logistic regression with randomisation arm, centre, 
observed/expected head- lung ratio, position of the liver, 
side of the defect, defect size and ventilation modality as 
independent variables.25 If necessary, multiple imputa-
tion using the fully conditional specification method will 
be used to account for missing data in the independent 
variables. We will perform a sensitivity analyses with adjust-
ment for the use of prostin and milrinone, to account for 
the effects of these vasodilators on PH.
The following analyses will be performed for the 
secondary outcomes. The distribution of VIS score in 
all study participants will be compared between t=0 and 
t=12 hours after initiation of drug administration using a 
Wilcoxon signed rank test. The distribution of changes 
in OI and VIS score from t=0 to t=12 and t=24 hours will 
be compared between the randomisation groups with 
a Mann- Whitney test. The overall mortality in the first 
year of life will be compared between the randomisation 
groups with Kaplan- Meier curves and the log- rank test. 
The number of treatment failures, the need for ECMO 
(in ECMO centres) and the need for medication for PH 
or chronic lung disease at discharge, and during the first 
year of life, will be compared between randomisation 
groups with χ2 tests. The number of study drug free days 
at day 14, the number of ventilation- free days until day 
28, the fraction of days with need for medical treatment 
(excluding the study drug) for PH during the hospital 
admission and the severity of chronic lung disease using 
the Bancalari definition will be compared between 
randomisation groups using Mann- Whitney tests. Deaths 
will be counted as the worst outcome in these analyses, 
in accordance with the intention- to- treat principle. The 
presence of PH at 28 days/discharge, 6 and 12 months 
according to the echocardiographic parameters will be 
compared between randomisation groups with a χ2 test.
To externally validate the pharmacokinetic model 
of sildenafil and its active metabolite (in NONMEM) 
normalised prediction distribution errors and visual 
predictive check will be used. Furthermore, the model 
will be used to predict the drug concentrations from the 
new data set using simulations, in which we expect that 
the difference will be less than 20%. To assess whether 
there is a relationship between the concentration of silde-
nafil, its active metabolite and the clinical effects, such as 
OI, VIS score and echocardiography measures, a Mann- 
Whitney or Student’s t- test will be used.
Safety reporting and trial oversight
All severe adverse events (SAEs) and suspected unex-
pected serious adverse reactions (SUSARs) are reported 
from the enrolment until 12- month follow- up. Persistent 
or significant disability or incapacity that was not expected 
with the given observed to expected lung to head ratio 
(O/E LHR) is evaluated as an SAE. An elective hospital 
admission is not a SAE. All SAEs and SUSARs are reported 
to the approving ethics committees in accordance with 
their requirements. We will report the SAEs and SUSARs 
that result in death or are life threatening within 7 days 
of first knowledge. All other SAEs and SUSARs will be 
reported within a period of maximum 15 days. Once a 
year throughout the clinical trial, we will submit a safety 
report to the approving ethics committees and compe-
tent authorities of the countries involved.
The trial will be monitored by qualified, independent 
monitors. The trial is classified as a trial with moderate 
risk and a specific monitoring plan is in place.
The data safety monitoring board will monitor the inci-
dence of mortality on a continuous basis. If at some point 
a large difference in mortality, defined as an absolute 
risk increase of 25%, between the two treatment groups 
is noticed, the data safety monitoring board may recom-
mend ending the study.
Insurance will cover compensation to patients who 
suffer harm from trial participation.
EthICS And dISSEMInAtIon
The trial will be submitted to the regulatory bodies and 
the local institutional review boards (IRB) in all partici-
pating countries. Important amendments will be commu-
nicated to all relevant parties. The study will be conducted 
according to the principles of the Declaration of Helsinki, 
in accordance with the Medical Research Involving 
Human Subjects Act and national rules and regulations 
on personal data protection. Parental informed consent 
will be obtained. The results of this study will be dissem-
inated via peer- reviewed publications and implemented 
in the international guidelines for the treatment of 
newborns with CDH.
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